{"id":2568,"date":"2022-06-08T13:59:54","date_gmt":"2022-06-08T17:59:54","guid":{"rendered":"https:\/\/neoaptamers.com\/?p=2568"},"modified":"2026-04-13T15:32:46","modified_gmt":"2026-04-13T19:32:46","slug":"why-have-aptamers-in-therapeutics-not-been-more-successful","status":"publish","type":"post","link":"https:\/\/neoaptamers.com\/es\/why-have-aptamers-in-therapeutics-not-been-more-successful\/","title":{"rendered":"Why Have Aptamers in Therapeutics Not Been More Successful?"},"content":{"rendered":"<p><span style=\"font-weight: 400;\">I love the confidence of those responding. Basically the winning category was that aptamers work great, they just have not been tried in enough applications.\u00a0<\/span><\/p>\n<p><span style=\"font-weight: 400;\">In my opinion, we should have provided a fifth option in this poll, All of the above\u2026\u00a0<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Successful monoclonal antibody based treatments are all based on the capacity of the antibody to induce an immune response once it has bound to its target. This is the fundamental principle behind Mab treatments. We do not expect aptamers to induce an immune response. This means that this entire scope of treatment applications are potentially not appropriate for aptamers. I think that aptamer applications in therapy are more likely to be in areas where a suppression of an immune response is desired, such as auto-immune diseases. Aptamer binding to the target in these cases has the potential to reduce antibody binding and thus reduce the severity of the response. We have explored the potential of aptamers for treatment of Alzheimer\u2019s disease as a means of reducing chronic inflammation in the brain.\u00a0<\/span><\/p>\n<p><span style=\"font-weight: 400;\">The next two options, aptamers clear to rapidly\u00a0 and aptamers do not bind well enough are related to each other. If aptamers bind to their target with sufficient strength then they will clear less rapidly. The rapid clearance of aptamers through the renal system is a tremendous potential advantage for aptamers in terms of favourable pharmacodynamics. Aptamers that bind aspecifically to other components in serum especially serum albumin may also have longer retention times.\u00a0<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Very definitely there have been insufficient clinical trials with aptamers in comparison with antibodies. The failure rate of clinical treatment trials is very high, and the failure rate of antibodies is in line with this. I think that the key to success for aptamers in therapeutic trials is appropriate positioning of the application. There is no point in developing aptamers to compete with antibodies in this area.\u00a0<\/span><\/p>\n<p><span style=\"font-weight: 400;\">The majority of our work with partners in therapeutics is the use of aptamers as vectors for the targeted delivery of drugs. We have the capacity to select aptamers for transmembrane receptors such that the selected aptamers either will induce endocytosis and thus can be used to carry other drugs (especially RNA drugs) into cells, or aptamers that will bind to transmembrane receptors and not induce endocytosis. This latter application is of interest for prophylactic applications of aptamers to prevent virus entry into cells, or to down regulate existing transmembrane receptor activity.\u00a0<\/span><\/p>\n<p><span style=\"font-weight: 400;\">If you are interested in discussing your aptamer based therapeutic application with us, <a href=\"https:\/\/neoaptamers.com\/es\/free-consultation\/\">please register on our website for a free consultation<\/a> and we look forward to talking with you.\u00a0<\/span><\/p>\n<p>&nbsp;<\/p>","protected":false},"excerpt":{"rendered":"<p>I love the confidence of those responding. Basically the winning category was that aptamers work great, they just have not been tried in enough applications.\u00a0 In my opinion, we should have provided a fifth option in this poll, All of the above\u2026\u00a0 Successful monoclonal antibody based treatments are all based on the capacity of the&hellip;&nbsp;<a href=\"https:\/\/neoaptamers.com\/es\/why-have-aptamers-in-therapeutics-not-been-more-successful\/\" rel=\"bookmark\">Leer m\u00e1s &raquo;<span class=\"screen-reader-text\">Why Have Aptamers in Therapeutics Not Been More Successful?<\/span><\/a><\/p>","protected":false},"author":2,"featured_media":2569,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"neve_meta_sidebar":"","neve_meta_container":"","neve_meta_enable_content_width":"off","neve_meta_content_width":70,"neve_meta_title_alignment":"","neve_meta_author_avatar":"","neve_post_elements_order":"","neve_meta_disable_header":"","neve_meta_disable_footer":"","neve_meta_disable_title":"","footnotes":""},"categories":[8],"tags":[],"class_list":["post-2568","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-aptamers"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Why Have Aptamers in Therapeutics Not Been More Successful?<\/title>\n<meta name=\"description\" content=\"Are there limitations to the abilities of aptamers in therapeutics or have there just been insufficient trials? Read our thoughts.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/neoaptamers.com\/es\/why-have-aptamers-in-therapeutics-not-been-more-successful\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Why Have Aptamers in Therapeutics Not Been More Successful?\" \/>\n<meta property=\"og:description\" content=\"Are there limitations to the abilities of aptamers in therapeutics or have there just been insufficient trials? Read our thoughts.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/neoaptamers.com\/es\/why-have-aptamers-in-therapeutics-not-been-more-successful\/\" \/>\n<meta property=\"og:site_name\" content=\"neoaptamers\" \/>\n<meta property=\"article:published_time\" content=\"2022-06-08T17:59:54+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-13T19:32:46+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/neoaptamers.com\/wp-content\/uploads\/2022\/06\/Screen-Shot-2022-06-03-at-8.58.48-AM.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1026\" \/>\n\t<meta property=\"og:image:height\" content=\"590\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Gregory Penner\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Gregory Penner\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/why-have-aptamers-in-therapeutics-not-been-more-successful\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/why-have-aptamers-in-therapeutics-not-been-more-successful\\\/\"},\"author\":{\"name\":\"Gregory Penner\",\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/#\\\/schema\\\/person\\\/641d6a3e016e13414b8d0d0ffd5847ad\"},\"headline\":\"Why Have Aptamers in Therapeutics Not Been More Successful?\",\"datePublished\":\"2022-06-08T17:59:54+00:00\",\"dateModified\":\"2026-04-13T19:32:46+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/why-have-aptamers-in-therapeutics-not-been-more-successful\\\/\"},\"wordCount\":447,\"publisher\":{\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/why-have-aptamers-in-therapeutics-not-been-more-successful\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/neoaptamers.com\\\/wp-content\\\/uploads\\\/2022\\\/06\\\/Screen-Shot-2022-06-03-at-8.58.48-AM.png\",\"articleSection\":[\"Aptamers\"],\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/why-have-aptamers-in-therapeutics-not-been-more-successful\\\/\",\"url\":\"https:\\\/\\\/neoaptamers.com\\\/why-have-aptamers-in-therapeutics-not-been-more-successful\\\/\",\"name\":\"Why Have Aptamers in Therapeutics Not Been More Successful?\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/why-have-aptamers-in-therapeutics-not-been-more-successful\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/why-have-aptamers-in-therapeutics-not-been-more-successful\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/neoaptamers.com\\\/wp-content\\\/uploads\\\/2022\\\/06\\\/Screen-Shot-2022-06-03-at-8.58.48-AM.png\",\"datePublished\":\"2022-06-08T17:59:54+00:00\",\"dateModified\":\"2026-04-13T19:32:46+00:00\",\"description\":\"Are there limitations to the abilities of aptamers in therapeutics or have there just been insufficient trials? Read our thoughts.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/why-have-aptamers-in-therapeutics-not-been-more-successful\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/neoaptamers.com\\\/why-have-aptamers-in-therapeutics-not-been-more-successful\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/why-have-aptamers-in-therapeutics-not-been-more-successful\\\/#primaryimage\",\"url\":\"https:\\\/\\\/neoaptamers.com\\\/wp-content\\\/uploads\\\/2022\\\/06\\\/Screen-Shot-2022-06-03-at-8.58.48-AM.png\",\"contentUrl\":\"https:\\\/\\\/neoaptamers.com\\\/wp-content\\\/uploads\\\/2022\\\/06\\\/Screen-Shot-2022-06-03-at-8.58.48-AM.png\",\"width\":1026,\"height\":590},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/why-have-aptamers-in-therapeutics-not-been-more-successful\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/neoaptamers.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Why Have Aptamers in Therapeutics Not Been More Successful?\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/#website\",\"url\":\"https:\\\/\\\/neoaptamers.com\\\/\",\"name\":\"Neoaptamers.com\",\"description\":\"Neoventures Biotechnology Inc.\",\"publisher\":{\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/neoaptamers.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/#organization\",\"name\":\"NeoVentures Biotechnology Inc.\",\"alternateName\":\"NVB\",\"url\":\"https:\\\/\\\/neoaptamers.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/neoaptamers.com\\\/wp-content\\\/uploads\\\/2024\\\/07\\\/NeoVentures-Biotechnology-Square-Logo-No-Text-1.png\",\"contentUrl\":\"https:\\\/\\\/neoaptamers.com\\\/wp-content\\\/uploads\\\/2024\\\/07\\\/NeoVentures-Biotechnology-Square-Logo-No-Text-1.png\",\"width\":500,\"height\":500,\"caption\":\"NeoVentures Biotechnology Inc.\"},\"image\":{\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.linkedin.com\\\/company\\\/neoventures-biotechnology-inc-\\\/\",\"https:\\\/\\\/www.reddit.com\\\/user\\\/NeoVenturesBiotech\\\/\",\"https:\\\/\\\/www.youtube.com\\\/@neoaptamers7964\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/#\\\/schema\\\/person\\\/641d6a3e016e13414b8d0d0ffd5847ad\",\"name\":\"Gregory Penner\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/de665d788f86991000373f8dc389e0f6dcbb9228ffc3b4920b098d16c7c491e8?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/de665d788f86991000373f8dc389e0f6dcbb9228ffc3b4920b098d16c7c491e8?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/de665d788f86991000373f8dc389e0f6dcbb9228ffc3b4920b098d16c7c491e8?s=96&d=mm&r=g\",\"caption\":\"Gregory Penner\"},\"description\":\"Dr. Gregory Penner academic training was a blend of very practical plant breeding theory combined with molecular biology. He has used this blend of biology and mathematics to first develop and lead a cereal biotechnology research team with the government of Canada and subsequently as a global research leader with Monsanto Inc. He has been a thought leader in aptamer development globally for the last twenty years as CEO and President of NeoVentures. \u00a0He has led this company to financial stability without outside investment with an integrated approach to aptamer discovery and commercialization. In 2015, he co- founded a second company, NeoNeuro in Paris France, focused on an innovative approach to identify Aptamarkers for complex diseases. Connect with Dr. Penner on LinkedIn or for company updates, follow NeoVentures. Click here to get in touch with our team.\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Why Have Aptamers in Therapeutics Not Been More Successful?","description":"Are there limitations to the abilities of aptamers in therapeutics or have there just been insufficient trials? Read our thoughts.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/neoaptamers.com\/es\/why-have-aptamers-in-therapeutics-not-been-more-successful\/","og_locale":"es_ES","og_type":"article","og_title":"Why Have Aptamers in Therapeutics Not Been More Successful?","og_description":"Are there limitations to the abilities of aptamers in therapeutics or have there just been insufficient trials? Read our thoughts.","og_url":"https:\/\/neoaptamers.com\/es\/why-have-aptamers-in-therapeutics-not-been-more-successful\/","og_site_name":"neoaptamers","article_published_time":"2022-06-08T17:59:54+00:00","article_modified_time":"2026-04-13T19:32:46+00:00","og_image":[{"width":1026,"height":590,"url":"https:\/\/neoaptamers.com\/wp-content\/uploads\/2022\/06\/Screen-Shot-2022-06-03-at-8.58.48-AM.png","type":"image\/png"}],"author":"Gregory Penner","twitter_card":"summary_large_image","twitter_misc":{"Escrito por":"Gregory Penner","Tiempo de lectura":"3 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/neoaptamers.com\/why-have-aptamers-in-therapeutics-not-been-more-successful\/#article","isPartOf":{"@id":"https:\/\/neoaptamers.com\/why-have-aptamers-in-therapeutics-not-been-more-successful\/"},"author":{"name":"Gregory Penner","@id":"https:\/\/neoaptamers.com\/#\/schema\/person\/641d6a3e016e13414b8d0d0ffd5847ad"},"headline":"Why Have Aptamers in Therapeutics Not Been More Successful?","datePublished":"2022-06-08T17:59:54+00:00","dateModified":"2026-04-13T19:32:46+00:00","mainEntityOfPage":{"@id":"https:\/\/neoaptamers.com\/why-have-aptamers-in-therapeutics-not-been-more-successful\/"},"wordCount":447,"publisher":{"@id":"https:\/\/neoaptamers.com\/#organization"},"image":{"@id":"https:\/\/neoaptamers.com\/why-have-aptamers-in-therapeutics-not-been-more-successful\/#primaryimage"},"thumbnailUrl":"https:\/\/neoaptamers.com\/wp-content\/uploads\/2022\/06\/Screen-Shot-2022-06-03-at-8.58.48-AM.png","articleSection":["Aptamers"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/neoaptamers.com\/why-have-aptamers-in-therapeutics-not-been-more-successful\/","url":"https:\/\/neoaptamers.com\/why-have-aptamers-in-therapeutics-not-been-more-successful\/","name":"Why Have Aptamers in Therapeutics Not Been More Successful?","isPartOf":{"@id":"https:\/\/neoaptamers.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/neoaptamers.com\/why-have-aptamers-in-therapeutics-not-been-more-successful\/#primaryimage"},"image":{"@id":"https:\/\/neoaptamers.com\/why-have-aptamers-in-therapeutics-not-been-more-successful\/#primaryimage"},"thumbnailUrl":"https:\/\/neoaptamers.com\/wp-content\/uploads\/2022\/06\/Screen-Shot-2022-06-03-at-8.58.48-AM.png","datePublished":"2022-06-08T17:59:54+00:00","dateModified":"2026-04-13T19:32:46+00:00","description":"Are there limitations to the abilities of aptamers in therapeutics or have there just been insufficient trials? Read our thoughts.","breadcrumb":{"@id":"https:\/\/neoaptamers.com\/why-have-aptamers-in-therapeutics-not-been-more-successful\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/neoaptamers.com\/why-have-aptamers-in-therapeutics-not-been-more-successful\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/neoaptamers.com\/why-have-aptamers-in-therapeutics-not-been-more-successful\/#primaryimage","url":"https:\/\/neoaptamers.com\/wp-content\/uploads\/2022\/06\/Screen-Shot-2022-06-03-at-8.58.48-AM.png","contentUrl":"https:\/\/neoaptamers.com\/wp-content\/uploads\/2022\/06\/Screen-Shot-2022-06-03-at-8.58.48-AM.png","width":1026,"height":590},{"@type":"BreadcrumbList","@id":"https:\/\/neoaptamers.com\/why-have-aptamers-in-therapeutics-not-been-more-successful\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/neoaptamers.com\/"},{"@type":"ListItem","position":2,"name":"Why Have Aptamers in Therapeutics Not Been More Successful?"}]},{"@type":"WebSite","@id":"https:\/\/neoaptamers.com\/#website","url":"https:\/\/neoaptamers.com\/","name":"Neoaptamers.com","description":"Neoventures Biotechnology Inc.","publisher":{"@id":"https:\/\/neoaptamers.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/neoaptamers.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/neoaptamers.com\/#organization","name":"NeoVentures Biotechnology Inc.","alternateName":"NVB","url":"https:\/\/neoaptamers.com\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/neoaptamers.com\/#\/schema\/logo\/image\/","url":"https:\/\/neoaptamers.com\/wp-content\/uploads\/2024\/07\/NeoVentures-Biotechnology-Square-Logo-No-Text-1.png","contentUrl":"https:\/\/neoaptamers.com\/wp-content\/uploads\/2024\/07\/NeoVentures-Biotechnology-Square-Logo-No-Text-1.png","width":500,"height":500,"caption":"NeoVentures Biotechnology Inc."},"image":{"@id":"https:\/\/neoaptamers.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.linkedin.com\/company\/neoventures-biotechnology-inc-\/","https:\/\/www.reddit.com\/user\/NeoVenturesBiotech\/","https:\/\/www.youtube.com\/@neoaptamers7964"]},{"@type":"Person","@id":"https:\/\/neoaptamers.com\/#\/schema\/person\/641d6a3e016e13414b8d0d0ffd5847ad","name":"Gregory Penner","image":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/secure.gravatar.com\/avatar\/de665d788f86991000373f8dc389e0f6dcbb9228ffc3b4920b098d16c7c491e8?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/de665d788f86991000373f8dc389e0f6dcbb9228ffc3b4920b098d16c7c491e8?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/de665d788f86991000373f8dc389e0f6dcbb9228ffc3b4920b098d16c7c491e8?s=96&d=mm&r=g","caption":"Gregory Penner"},"description":"Dr. Gregory Penner academic training was a blend of very practical plant breeding theory combined with molecular biology. He has used this blend of biology and mathematics to first develop and lead a cereal biotechnology research team with the government of Canada and subsequently as a global research leader with Monsanto Inc. He has been a thought leader in aptamer development globally for the last twenty years as CEO and President of NeoVentures. \u00a0He has led this company to financial stability without outside investment with an integrated approach to aptamer discovery and commercialization. In 2015, he co- founded a second company, NeoNeuro in Paris France, focused on an innovative approach to identify Aptamarkers for complex diseases. Connect with Dr. Penner on LinkedIn or for company updates, follow NeoVentures. Click here to get in touch with our team."}]}},"_links":{"self":[{"href":"https:\/\/neoaptamers.com\/es\/wp-json\/wp\/v2\/posts\/2568","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/neoaptamers.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/neoaptamers.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/neoaptamers.com\/es\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/neoaptamers.com\/es\/wp-json\/wp\/v2\/comments?post=2568"}],"version-history":[{"count":3,"href":"https:\/\/neoaptamers.com\/es\/wp-json\/wp\/v2\/posts\/2568\/revisions"}],"predecessor-version":[{"id":6519,"href":"https:\/\/neoaptamers.com\/es\/wp-json\/wp\/v2\/posts\/2568\/revisions\/6519"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/neoaptamers.com\/es\/wp-json\/wp\/v2\/media\/2569"}],"wp:attachment":[{"href":"https:\/\/neoaptamers.com\/es\/wp-json\/wp\/v2\/media?parent=2568"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/neoaptamers.com\/es\/wp-json\/wp\/v2\/categories?post=2568"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/neoaptamers.com\/es\/wp-json\/wp\/v2\/tags?post=2568"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}